AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05717764
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Trial: NCT06351917
Drug: PlexoZome® Levagen® topical spray solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PlexoZome® Levagen® topical spray solution 10mg/g providing 1.8mg active per pump
Trial: NCT06351917
Drug: Placebo topical spray solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical spray solution topical spray solution 0mg/g providing 0mg active per pump
Trial: NCT05319756
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
Trial: NCT03636958
Drug: conventional antiepileptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
Trial: NCT00378456
Drug: Antioxidants- (Vitamins A,C,E Selenium and Zinc)
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05724485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.45 grams of Maltodextrin orally per day before bedtime
Trial: NCT05452005
Drug: [18F]-αvβ6-BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
Trial: NCT05512910
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
Trial: NCT04879823
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Trial: NCT04879823
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Trial: NCT04879823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
Trial: NCT06488105
Drug: Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
RxNorm normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
Trial: NCT05243602
Drug: Switch to B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
Trial: NCT05243602
Drug: Continue current regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
Trial: NCT06516562
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure
Trial: NCT05813249
Drug: Rybelsus Oral Product
RxNorm normalized name: Rybelsus Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Semaglutide
Trial: NCT05813249
Drug: Ozempic Injectable Product
RxNorm normalized name: Ozempic Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Semaglutide
Trial: NCT05045638
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral dose
Trial: NCT05584761
Drug: unrelated umbilical cord blood
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection.
Trial: NCT05977699
Drug: salbutamol aqueous solution
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
Trial: NCT05563961
Drug: Panadol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
Trial: NCT05563961
Drug: SafeTynadol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)
Trial: NCT06383507
Drug: CHT101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
Trial: NCT05832489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.
Trial: NCT05602961
Drug: BNT162b2/COMIRNATY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active control
Trial: NCT06645522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
Trial: NCT06355856
Drug: DNN.22.17.036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply twice daily to the affected area and around it.
Trial: NCT06025630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
Trial: NCT05425355
Drug: Intravenous (IV) placebo plus oral acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
Trial: NCT04764383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).
Trial: NCT06083844
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by mouth
Trial: NCT06168994
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiodarone vs eplerenone in AF
Trial: NCT05048589
Drug: Standard-Dose Quadrivalent Influenza Vaccine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
Trial: NCT05048589
Drug: High-Dose Quadrivalent Influenza Vaccine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
Trial: NCT05676476
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment to goal of less than 140/90 mmHg
Trial: NCT05769920
Drug: TTHX1114(NM141) Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop twice daily
Trial: NCT06585644
Drug: Furmonertinib in combination with Anrotinib and chemotherapy
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
Trial: NCT05952713
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with an antidepressant according to Danish register data.
Trial: NCT05313802
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05775718
Drug: Zoster Vaccine Recombinant
RxNorm normalized name: zoster vaccine recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT06716970
Drug: QR12000 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QR12000 75mg QD
Trial: NCT06716970
Drug: QR12000 75mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of QR12000 75mg QD
Trial: NCT06716970
Drug: QR12000 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QR12000 150mg QD
Trial: NCT06716970
Drug: QR12000 150mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of QR12000 150mg QD
Trial: NCT05831995
Drug: ABM-168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
Trial: NCT05266963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06204120
Drug: LPM3480392 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA administration
Trial: NCT06204120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA administration
Trial: NCT05066230
Drug: KSI-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT06512116
Drug: SIBP-A17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design.
Trial: NCT05610254
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Trial: NCT06030258
Drug: IN10018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally taken once daily
Trial: NCT04618575
Drug: Ursodeoxycholic acid combined with total glucosides of paeony
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid combined with total glucosides of paeony
Trial: NCT04618575
Drug: Ursodeoxycholic acid only
RxNorm normalized name: Ursodeoxycholic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid only
Trial: NCT00367419
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06083480
Drug: GlyNAC (combination of glycine and n-acetylcysteine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
Trial: NCT06083480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
Trial: NCT05273775
Drug: HRS5091 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS5091 Tablets once daily
Trial: NCT05273775
Drug: Rosuvastatin Calcium Tablets
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin Calcium Tablets single dose
Trial: NCT05219799
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Trial: NCT06006559
Drug: EYU688
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EYU688 administered by oral route
Trial: NCT06006559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally as capsules
Trial: NCT04392037
Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
Trial: NCT05043298
Drug: IBI 360 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI 360 dose level of escalation IV Q3W Day 1
Trial: NCT05858047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily (QD)
Trial: NCT05858047
Drug: SYHX1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily (QD)
Trial: NCT06285643
Drug: AAV2-GDNF Gene therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Trial: NCT06072781
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT05878522
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 capsules administered Q12 hours for 5 doses
Trial: NCT06646783
Drug: [68Ga]Ga-NODAGA-SNA014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.
Trial: NCT06585774
Drug: INCA034176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06585774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06585774
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/IV Infusion
Trial: NCT04973111
Drug: Placebo as SC Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06385418
Drug: Colonic local administration of fluorouracil with enhanced adhesion
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
Trial: NCT05725213
Drug: Metvix® 160 mg/g Creme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are treated with Metvix creme and exposed to artificial daylight
Trial: NCT05886998
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium (Generic, 5000 IU/ml ampoules)
Trial: NCT05414266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
Trial: NCT05414266
Drug: SADBE 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
Trial: NCT04530565
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04530565
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04530565
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT04674735
Drug: APSLXR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral coated tablets once a day for 60 days.
Trial: NCT05457296
Drug: Hydrocortisone (capsule)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
Trial: NCT06290557
Drug: HY_133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A recombinant chimeric bacteriophage endolysin HY-133
Trial: NCT06290557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05971186
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage Form: Tablet Dosage: 1 tablet of Ibuprofen (400 mg) Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption